CliffBio
small molecule

IMVEXXY

ESTRADIOL

Loss of exclusivityFebruary 2034latest FDA-listed patent expiry
CompanyMayne Pharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameIMVEXXY
Active ingredientESTRADIOL
Strength0.01MG
Dosage formINSERT
RouteVAGINAL
ModalitySmall molecule
FDA approvalMay 2018
Marketing statusRX

Listed patents

PatentExpiresType
11266661February 2034use U-2317
10398708November 2032use U-2614
10471072November 2032use U-2316
10537581November 2032product
11246875November 2032use U-2316
11241445November 2032use U-2316
10668082November 2032use U-2317
10568891November 2032use U-2316
9180091November 2032product
11497709November 2032use U-2317
10835487November 2032use U-2316
10888516November 2032use U-2317
11351182November 2032use U-2317
11116717November 2032product
11123283November 2032product
11065197November 2032product
10806697November 2032product
9289382November 2032product
10258630November 2032use U-2317
11304959November 2032product

More from Mayne Pharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

IMVEXXY patent cliff — loss of exclusivity February 2034 | CliffBio